Genzyme Renagel Marketing Message Will Focus On Lipid-Lowering Effect
This article was originally published in The Pink Sheet Daily
Executive Summary
Phosphate binder may face competition from Shire’s Fosrenol and Amgen’s cinacalcet in the near term. Genzyme views cinacalcet as a "complementary product" rather than a direct competitor.
You may also be interested in...
Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End
Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.
Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End
Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.
Abbott Will Grow Zemplar Sales With Oral Formulation, Predialysis Use
An NDA filing for oral Zemplar in predialysis chronic kidney disease patients is slated for this summer. Amgen's Sensipar will have "no effect" on the Zemplar I.V. business, Abbott says.